zk1414997.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report: May 22, 2014

PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

001-31392
  
98-0351734
(Commission File Number)
  
(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel
  
31905
(Address of Principal Executive Offices)
  
(Zip Code)

011 972 74 710 7171
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

Pluristem Therapeutics Inc. (the “Company”), held its annual meeting of stockholders on May 22, 2014. The results of the stockholder voting at the annual meeting are set forth below.

Stockholders voted on the matters set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name
  
For
    
Against
    
Abstain
    
Broker Non-Votes
  
                         
Zami Aberman
    
15,225,574
      
3,653,462
      
26,907
      
15,245,366
  
                                 
Israel Ben-Yoram
    
18,611,618
      
130,728
      
163,597
      
15,245,366
  
                                 
Isaac Braun
    
18,667,408
      
72,388
      
166,147
      
15,245,366
  
                                 
Mark Germain
    
18,604,030
      
138,105
      
163,808
      
15,245,366
  
                                 
Moria Kwiat
    
18,602,861
      
143,824
      
159,258
      
15,245,366
  
                                 
Hava Meretzki
    
18,635,058
      
136,101
      
134,784
      
15,245,366
  
                                 
Nachum Rosman
    
18,631,094
      
109,942
      
164,907
      
15,245,366
  
                                 
Doron Shorrer
    
16,241,054
      
2,505,521
      
159,368
      
15,245,366
  
 
Proposal No. 2 — Amendment to the Company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock
 
For
    
Against
    
Abstain
    
Broker Non-Votes
  
                     
30,674,537
    
2,725,415
    
177,798
    
573,559
  
 
Proposal No. 3 — Ratification of the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2014

For
    
Against
    
Abstain
    
Broker Non-Votes
  
                     
32,771,414
    
393,910
    
184,128
    
N/A
  

The results reported above are final voting results.

 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PLURISTEM THERAPEUTICS INC.
   
Date: May 22, 2014
By:
/s/ Boaz Gur-Lavie
 
Name:
Boaz Gur-Lavie
 
Title:
Chief Financial Officer and Secretary